Tag: Astrazeneca
AstraZeneca: Stifel lowers its target, cautious for 2023
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: Stifel lowers target, cautious for 2023
(CercleFinance.com) – Stifel maintains its ‘buy’ recommendation on AstraZeneca stock, but reduces its price target on the stock from 13,300p to 12,800p. While the laboratory will present its 2022 annual…
AstraZeneca: New approval for Tezspire in Europe
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: Agreement for the acquisition of the American CinCor
(CercleFinance.com) – AstraZeneca announced Monday that it has reached an agreement to acquire CinCor, an American company specializing in the treatment of hypertension and chronic kidney failure. In a press…
AstraZeneca: two new approvals in Europe
(CercleFinance.com) – AstraZeneca announced on Wednesday that Lynparza has been authorized by the European Union for the treatment of prostate cancer. The green light from Brussels concerns the use of…
AstraZeneca: positive opinions in liver and lung cancers
(CercleFinance.com) – AstraZeneca indicates that its Imfinzi-Imjudo combination is recommended by the CHMP for marketing authorization in the European Union, in the first-line treatment of adult patients with advanced liver…
AstraZeneca: favorable opinion in breast cancer
(CercleFinance.com) – AstraZeneca announces that its Enhertu, co-developed with Daiichi Sankyo, has been recommended by the CHMP for approval in the EU as monotherapy for the treatment of adult patients…
AstraZeneca: conclusive trial in breast cancer
(CercleFinance.com) – AstraZeneca announces that a phase III trial involving the combination of capivasertib and Faslodex (fulvestrant) showed ‘a clinically and statistically significant improvement’ in progression-free survival (PFS) in patients…
AstraZeneca: Bank of America reiterates the purchase
(CercleFinance.com) – Bank of America reiterated its buy recommendation on AstraZeneca on Wednesday, with a target price of 12,500 pence, believing that the valuation of the laboratory, its growth and…
AstraZeneca: Green light in China for Alexion treatment
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: Towards a new indication for Lynparza
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: green light in China for Alexion treatment
(CercleFinance.com) – AstraZeneca today announced the availability of the first rare disease treatment from Alexion, its rare disease subsidiary of AstraZeneca, in China. The company thus announces the availability of…